Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus

Single center, open label crossover study with 2 treatment phases in healthy volunteers.

The potential of phenotypic drug probes to predict drug-drug interactions between tacrolimus, voriconazole and rifampin will be assessed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Drug Interactions Kidney Transplantation

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

University Hospitals Leuven

Leuven, Vlaams-Brabant, 3000, Belgium

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male
Age over 18 years
Written informed consent

Exclusion criteria

Female
Medical comorbidities
Use of concomitant medication

Treatment and study plan

Voriconazole

Drug

Other names: Vfend

Rifampin

Drug

Other names: Rifadin; Rifadine

Primary outcomes

Change in tacrolimus area under the curve

Time frame: 2 weeks

assessed twice: once after each treatment

Sponsors and collaborators

Lead sponsor

Universitaire Ziekenhuizen KU Leuven

Other

Registry information

Important dates

Study start: 2016
Primary completion: 2017
Study completion: 2017
First posted: Oct 15, 2015
Registry last updated: Aug 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed